Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

IMCR

Immunocore Holdings plc ADR

Dec 05 • 04:00PM ET

38.78

-1.44 -3.57 %

Healthcare • Biotechnology • United Kingdom • NASD

Peers: MRNA REGN AMGN VRTX BIIB BNTX BMY GILD INCY NVAX

| Held by: IBB SPDW GWX SBIO CANC ONEQ ISCF BBP TMED IBBQ

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.58	Insider Own	0.76%	Shs Outstand	50.47M	Perf Week	-1.82%
Market Cap	1.96B	Forward P/E	-	EPS next Y	-0.87	Insider Trans	-37.29%	Shs Float	50.08M	Perf Month	25.91%
Enterprise Value	1.50B	PEG	-	EPS next Q	-0.19	Inst Own	97.66%	Short Float	17.51%	Perf Quarter	5.84%
Income	-29.11M	P/S	5.15	EPS this Y	67.03%	Inst Trans	3.08%	Short Ratio	28.10	Perf Half Y	4.11%
Sales	379.71M	P/B	4.96	EPS next Y	-160.15%	ROA	-2.66%	Short Interest	8.77M	Perf YTD	31.46%
Book/sh	7.81	P/C	2.19	EPS next 5Y	-1.48%	ROE	-7.52%	52W High	40.53 -4.32%	Perf Year	20.36%
Cash/sh	17.68	P/FCF	684.34	EPS past 3/5Y	37.84% 20.08%	ROIC	-3.50%	52W Low	23.15 67.52%	Perf 3Y	-38.26%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	104.15% 56.79%	Gross Margin	98.34%	Volatility	6.05% 4.64%	Perf 5Y	-
Dividend TTM	-	EV/Sales	3.95	EPS Y/Y TTM	38.72%	Oper. Margin	-11.87%	ATR (14)	1.77	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.97	Sales Y/Y TTM	27.51%	Profit Margin	-7.67%	RSI (14)	57.11	Recom	1.65
Dividend Gr. 3/5Y	- -	Current Ratio	6.00	EPS Q/Q	-102.09%	SMA20	3.31%	Beta	0.77	Target Price	64.30
Payout	-	Debt/Eq	1.10	Sales Q/Q	27.14%	SMA50	10.70%	Rel Volume	0.77	Prev Close	40.22
Employees	493	LT Debt/Eq	1.09	Earnings	Nov 06 BMO	SMA200	18.53%	Avg Volume	312.08K	Price	38.78
IPO	Feb 05, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	100.00% 1.81%	Trades		Volume	239,442	Change	-3.57%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-31-25	Initiated	Wells Fargo	Overweight	$60
Sep-18-25	Resumed	Guggenheim	Neutral
Aug-25-25	Resumed	Jefferies	Buy	$48
May-27-25	Initiated	Deutsche Bank	Buy	$65
Dec-13-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$74 → $35
Nov-11-24	Downgrade	Mizuho	Outperform → Neutral	$72 → $38
Oct-24-24	Initiated	UBS	Sell	$24
Oct-07-24	Downgrade	Guggenheim	Buy → Neutral
Apr-29-24	Initiated	Leerink Partners	Outperform	$74
Nov-20-23	Resumed	JP Morgan	Overweight	$60
Nov-02-23	Initiated	Cantor Fitzgerald	Overweight
Oct-31-23	Initiated	Robert W. Baird	Outperform	$84
Sep-13-23	Upgrade	JP Morgan	Neutral → Overweight	$9 → $22
Sep-13-23	Initiated	Needham	Buy	$75
Aug-16-23	Initiated	CapitalOne	Overweight	$84
Jul-17-23	Initiated	Canaccord Genuity	Hold	$67
Mar-31-23	Initiated	Mizuho	Buy	$70
Mar-30-23	Initiated	Guggenheim	Buy	$85
Mar-24-23	Initiated	Bryan Garnier	Buy	$16
Dec-16-22	Upgrade	Goldman	Neutral → Buy	$33 → $80

Show Previous Ratings

Nov-10-25 07:00AM	Immunocore to present at upcoming investor conferences (GlobeNewswire)
Nov-07-25 08:00AM	Immunocore presents Phase 1 data for hepatitis B candidate at AASLD's The Liver Meeting (GlobeNewswire) +6.03%
Nov-06-25 10:00AM	Immunocore (IMCR) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
07:00AM	Immunocore reports third quarter financial results and provides a business update (GlobeNewswire)
Nov-03-25 11:19AM	Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards? (Zacks)
09:33AM	Loading…
Oct-31-25 09:33AM	Apple upgraded, Comcast downgraded: Wall Street's top analyst calls (The Fly)
Oct-27-25 06:42PM	Growth Picks: 3 Low-Cost Stocks That Could Double in Value (MarketBeat)
Oct-20-25 11:08PM	H.C. Wainwright Remains Bullish on Immunocore Holdings plc (IMCR) (Insider Monkey)
Sep-04-25 07:00AM	Immunocore to present at upcoming investor conferences (GlobeNewswire)
Aug-08-25 12:47PM	IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi (Zacks)
11:45AM	Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y (Zacks)
11:19AM	Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus (Zacks)
11:01AM	Immunocore Holdings PLC (IMCR) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
10:26AM	PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues (Zacks)
Aug-07-25 11:20AM	MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View (Zacks)
11:00AM	Loading…
11:00AM	Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates (Zacks)
10:08AM	Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
10:04AM	Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth (Zacks)
09:30AM	Compared to Estimates, Immunocore (IMCR) Q2 Earnings: A Look at Key Metrics (Zacks)
08:17AM	ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum (Zacks)
07:00AM	Immunocore reports second quarter financial results and provides a business update (GlobeNewswire)
Aug-06-25 12:16PM	Novo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US Hurdles (Zacks)
11:57AM	HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View (Zacks)
11:51AM	BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark (Zacks)
11:48AM	RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down (Zacks)
11:43AM	Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
11:42AM	ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises (Zacks)
11:07AM	Perrigo Beats on Q2 Earnings & Sales, Stock Down on '25 Sales View Cut (Zacks)
09:22AM	JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut (Zacks)
Aug-05-25 12:21PM	ZTS Q2 Earnings & Revenues Beat Estimates, '25 Outlook Raised (Zacks)
12:12PM	Loading…
12:12PM	TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line (Zacks)
11:54AM	CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption (Zacks)
11:36AM	AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y (Zacks)
11:33AM	VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study Goal (Zacks)
10:17AM	BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View (Zacks)
08:59AM	KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook (Zacks)
Aug-01-25 12:04PM	CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down (Zacks)
11:49AM	FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales (Zacks)
Jul-31-25 10:37AM	Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises (Zacks)
10:15AM	UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y (Zacks)
02:00AM	Immunocore to report second quarter 2025 financial results and host call on August 7, 2025 (GlobeNewswire)
Jul-30-25 10:23AM	Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales (Zacks)
Jul-24-25 09:55AM	Wall Street Analysts See a 72.34% Upside in Immunocore (IMCR): Can the Stock Really Move This High? (Zacks)
Jul-08-25 10:54AM	COGT Stock Soars on Phase III Systemic Mastocytosis Study Success (Zacks)
10:38AM	MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy (Zacks)
Jul-03-25 10:32AM	Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study (Zacks)
Jul-02-25 10:32AM	Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli (Zacks)
09:28AM	5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment (Zacks)
Jul-01-25 10:50AM	Biogen Begins Phase III Felzartamab Study for Third Kidney Disease (Zacks)
Jun-30-25 11:40AM	RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome (Zacks)
08:00AM	Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS Regions (GlobeNewswire)
Jun-25-25 11:17AM	KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study (Zacks)
11:14AM	Strength Seen in Kamada (KMDA): Can Its 9.5% Jump Turn into More Strength? (Zacks)
11:06AM	Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU (Zacks)
10:02AM	Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag (Zacks)
Jun-24-25 11:58AM	CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication (Zacks)
09:04AM	FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer (Zacks)
Jun-23-25 11:25AM	NVO Reports New Positive Phase III Data on Mim8 in Hemophilia A (Zacks)
09:53AM	FDA Extends INCY's Application for Opzelura Label Expansion (Zacks)
09:15AM	J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications (Zacks)
Jun-20-25 11:51AM	CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech (Zacks)
Jun-17-25 12:08PM	Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics (Zacks)
12:02PM	Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy (Zacks)
10:30AM	AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study (Zacks)
Jun-16-25 08:45AM	SRPT Plummets on Second Patient Death After DMD Gene Therapy Infusion (Zacks) -5.10%
Jun-05-25 10:03AM	FDA Grants Platform Technology Tag to Sarepta's Gene Therapy Vector (Zacks)
Jun-03-25 11:53AM	TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises (Zacks)
11:41AM	FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch (Zacks)
Jun-02-25 09:55AM	Wall Street Analysts Think Immunocore (IMCR) Could Surge 65.22%: Read This Before Placing a Bet (Zacks) +5.60%
07:00AM	Immunocore to present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-25 09:29AM	Is it a Good Idea to Invest in Immunocore Stock Right Now? (Zacks)
May-16-25 09:55AM	Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High? (Zacks)
May-09-25 08:48AM	PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates (Zacks)
May-08-25 07:31AM	New Strong Buy Stocks for May 8th (Zacks)
May-07-25 12:09PM	ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down (Zacks) +6.63%
09:30AM	Compared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key Metrics (Zacks)
08:59AM	BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates (Zacks)
07:40AM	CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks (Zacks)
07:00AM	Immunocore reports first quarter financial results and provides a business update (GlobeNewswire)
May-06-25 01:12PM	CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall (Zacks) -8.39%
11:59AM	VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened (Zacks)
09:39AM	AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y (Zacks)
May-02-25 11:10AM	Alkermes' Q1 Earnings and Revenues Fall Short of Estimates (Zacks)
07:53AM	Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates (Zacks)
Apr-30-25 09:55AM	Wall Street Analysts Think Immunocore (IMCR) Could Surge 107.45%: Read This Before Placing a Bet (Zacks)
09:07AM	Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y (Zacks)
Apr-27-25 09:22AM	Immunocore Holdings: A Name On My Watch List (Seeking Alpha)
Apr-02-25 11:49AM	Hospitals Experience FOMO In Adopting Delcath's PHP Treatment (Seeking Alpha)
08:00AM	Immunocore to present at upcoming investor conferences (GlobeNewswire)
Mar-25-25 10:46AM	Immunocore Holdings plc (IMCR): Among Stocks Receiving the Most Insider Love in March (InsiderMonkey)
Mar-21-25 10:21AM	Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last? (Zacks)
Mar-10-25 03:00PM	Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 (GlobeNewswire)
Mar-03-25 07:00AM	Immunocore to present at upcoming investor conferences (GlobeNewswire)
Feb-27-25 02:07AM	Immunocore Holdings PLC (IMCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
02:02AM	Q4 2024 Immunocore Holdings PLC Earnings Call (Thomson Reuters StreetEvents)
Feb-26-25 07:00AM	Immunocore reports fourth quarter and full year 2024 financial results and provides a business update (GlobeNewswire) +5.34%
Feb-25-25 10:32AM	Earnings To Watch: Immunocore Holdings PLC (IMCR) Reports Q4 2024 Result (GuruFocus.com)
Feb-20-25 03:00AM	Lillys former M&A chief scours the landscape for potential deals as Immunocores new CFO (Pharma Voice)
Feb-19-25 07:00AM	Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025 (GlobeNewswire)
Jan-13-25 09:55AM	Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's is How to Trade (Zacks)

Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX - Immune mobilizing monoclonal TCRs Against X disease. Its lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Berman David M	HEAD OF R&D	Nov 26 '25	Option Exercise	17.46	69,404	1,211,794	69,404	Dec 01 04:10 PM
Berman David M	HEAD OF R&D	Nov 28 '25	Option Exercise	17.46	5,521	96,397	5,521	Dec 01 04:10 PM
Berman David M	HEAD OF R&D	Nov 26 '25	Sale	40.12	69,404	2,784,488	0	Dec 01 04:10 PM
Berman David M	HEAD OF R&D	Nov 28 '25	Sale	40.09	5,521	221,337	0	Dec 01 04:10 PM
Berman David M	HEAD OF R&D	Nov 25 '25	Option Exercise	17.46	18,020	314,629	18,020	Nov 26 04:10 PM
Berman David M	HEAD OF R&D	Nov 24 '25	Option Exercise	17.46	100	1,746	100	Nov 26 04:10 PM
Berman David M	HEAD OF R&D	Nov 25 '25	Sale	40.03	18,020	721,341	0	Nov 26 04:10 PM
Berman David M	HEAD OF R&D	Nov 24 '25	Sale	40.00	100	4,000	0	Nov 26 04:10 PM
David M. Berman	Officer	Nov 24 '25	Proposed Sale	39.35	136,790	5,382,687		Nov 24 04:56 PM
Berman David M	HEAD OF R&D	Sep 30 '25	Option Exercise	17.46	61,849	1,079,884	61,849	Oct 02 04:10 PM
Berman David M	HEAD OF R&D	Sep 30 '25	Sale	35.23	61,849	2,178,940	0	Oct 02 04:10 PM
Berman David M	HEAD OF R&D	Sep 12 '25	Option Exercise	17.46	22,532	393,409	22,532	Sep 16 04:15 PM
Berman David M	HEAD OF R&D	Sep 15 '25	Option Exercise	17.46	200	3,492	200	Sep 16 04:15 PM
Berman David M	HEAD OF R&D	Sep 12 '25	Sale	35.67	22,532	803,699	0	Sep 16 04:15 PM
Berman David M	HEAD OF R&D	Sep 15 '25	Sale	35.01	200	7,002	0	Sep 16 04:15 PM
Berman David M	HEAD OF R&D	Sep 10 '25	Option Exercise	17.46	31,338	547,161	31,338	Sep 12 04:10 PM
Berman David M	HEAD OF R&D	Sep 11 '25	Option Exercise	17.46	19,081	333,154	19,081	Sep 12 04:10 PM
Berman David M	HEAD OF R&D	Sep 10 '25	Sale	36.14	31,338	1,132,709	0	Sep 12 04:10 PM
Berman David M	HEAD OF R&D	Sep 11 '25	Sale	36.28	19,081	692,259	0	Sep 12 04:10 PM
David M. Berman	Officer	Sep 10 '25	Proposed Sale	36.59	135,000	4,939,650		Sep 10 04:35 PM
BAKER BROS. ADVISORS LP	Director	Mar 17 '25	Buy	29.72	807,338	23,993,224	2,144,060	Mar 19 06:40 PM
Brian Di Donato	affiliate	Mar 17 '25	Proposed Sale	30.00	100,000	3,000,000		Mar 17 04:24 PM
Brian Di Donato	affiliate	Mar 14 '25	Proposed Sale	29.13	56,250	1,638,511		Mar 14 05:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMCR

Immunocore Holdings plc ADR

Upgrade your FINVIZ experience